CA2870569A1 - Crystal form of cabazitaxel and preparation method thereof - Google Patents
Crystal form of cabazitaxel and preparation method thereof Download PDFInfo
- Publication number
- CA2870569A1 CA2870569A1 CA2870569A CA2870569A CA2870569A1 CA 2870569 A1 CA2870569 A1 CA 2870569A1 CA 2870569 A CA2870569 A CA 2870569A CA 2870569 A CA2870569 A CA 2870569A CA 2870569 A1 CA2870569 A1 CA 2870569A1
- Authority
- CA
- Canada
- Prior art keywords
- cabazitaxel
- crystalline form
- carbon atoms
- dissolving
- crystallizing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- BMQGVNUXMIRLCK-OAGWZNDDSA-N cabazitaxel Chemical compound O([C@H]1[C@@H]2[C@]3(OC(C)=O)CO[C@@H]3C[C@@H]([C@]2(C(=O)[C@H](OC)C2=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=3C=CC=CC=3)C[C@]1(O)C2(C)C)C)OC)C(=O)C1=CC=CC=C1 BMQGVNUXMIRLCK-OAGWZNDDSA-N 0.000 title claims abstract description 175
- 229960001573 cabazitaxel Drugs 0.000 title claims abstract description 174
- 238000002360 preparation method Methods 0.000 title abstract description 10
- 239000013078 crystal Substances 0.000 title abstract 2
- -1 ester compound Chemical class 0.000 claims abstract description 18
- 239000003814 drug Substances 0.000 claims abstract description 9
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 54
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 45
- 238000000034 method Methods 0.000 claims description 43
- 239000000203 mixture Substances 0.000 claims description 42
- 125000004432 carbon atom Chemical group C* 0.000 claims description 41
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 31
- 238000000634 powder X-ray diffraction Methods 0.000 claims description 22
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 claims description 17
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 17
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 15
- 150000001335 aliphatic alkanes Chemical class 0.000 claims description 15
- 150000001298 alcohols Chemical class 0.000 claims description 14
- 238000001035 drying Methods 0.000 claims description 14
- TZIHFWKZFHZASV-UHFFFAOYSA-N methyl formate Chemical compound COC=O TZIHFWKZFHZASV-UHFFFAOYSA-N 0.000 claims description 12
- 238000010438 heat treatment Methods 0.000 claims description 9
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 6
- WPHGSKGZRAQSGP-UHFFFAOYSA-N methylenecyclohexane Natural products C1CCCC2CC21 WPHGSKGZRAQSGP-UHFFFAOYSA-N 0.000 claims description 6
- 230000001093 anti-cancer Effects 0.000 claims description 4
- 238000001914 filtration Methods 0.000 claims description 4
- LTMRRSWNXVJMBA-UHFFFAOYSA-L 2,2-diethylpropanedioate Chemical compound CCC(CC)(C([O-])=O)C([O-])=O LTMRRSWNXVJMBA-UHFFFAOYSA-L 0.000 claims description 3
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 3
- 229960001701 chloroform Drugs 0.000 claims description 3
- UOCLXMDMGBRAIB-UHFFFAOYSA-N 1,1,1-trichloroethane Chemical compound CC(Cl)(Cl)Cl UOCLXMDMGBRAIB-UHFFFAOYSA-N 0.000 claims description 2
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 claims description 2
- VFWCMGCRMGJXDK-UHFFFAOYSA-N 1-chlorobutane Chemical compound CCCCCl VFWCMGCRMGJXDK-UHFFFAOYSA-N 0.000 claims description 2
- SNMVRZFUUCLYTO-UHFFFAOYSA-N n-propyl chloride Chemical compound CCCCl SNMVRZFUUCLYTO-UHFFFAOYSA-N 0.000 claims description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 3
- 229920000297 Rayon Polymers 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 abstract description 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 abstract description 4
- 238000011282 treatment Methods 0.000 abstract description 4
- 239000002552 dosage form Substances 0.000 abstract description 3
- 239000002904 solvent Substances 0.000 abstract description 3
- 229940079593 drug Drugs 0.000 abstract description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 14
- 239000008213 purified water Substances 0.000 description 12
- 239000012453 solvate Substances 0.000 description 10
- 238000002411 thermogravimetry Methods 0.000 description 10
- 238000002329 infrared spectrum Methods 0.000 description 9
- 238000002425 crystallisation Methods 0.000 description 8
- 230000008025 crystallization Effects 0.000 description 8
- 238000000113 differential scanning calorimetry Methods 0.000 description 6
- 239000012535 impurity Substances 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- 238000013112 stability test Methods 0.000 description 5
- 239000000243 solution Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 229960003668 docetaxel Drugs 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000002834 transmittance Methods 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 206010062904 Hormone-refractory prostate cancer Diseases 0.000 description 2
- 238000004566 IR spectroscopy Methods 0.000 description 2
- 102000004243 Tubulin Human genes 0.000 description 2
- 108090000704 Tubulin Proteins 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 229940127557 pharmaceutical product Drugs 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- ZVAFCKLQJCZGAP-WDEREUQCSA-N (2r,3s)-2-hydroxy-3-[(2-methylpropan-2-yl)oxycarbonylamino]-3-phenylpropanoic acid Chemical compound CC(C)(C)OC(=O)N[C@H]([C@@H](O)C(O)=O)C1=CC=CC=C1 ZVAFCKLQJCZGAP-WDEREUQCSA-N 0.000 description 1
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-N Formic acid Chemical group OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 1
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 1
- 102000029749 Microtubule Human genes 0.000 description 1
- 108091022875 Microtubule Proteins 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000001946 anti-microtubular Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 150000004683 dihydrates Chemical group 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000016507 interphase Effects 0.000 description 1
- ULYZAYCEDJDHCC-UHFFFAOYSA-N isopropyl chloride Chemical compound CC(C)Cl ULYZAYCEDJDHCC-UHFFFAOYSA-N 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- 210000004688 microtubule Anatomy 0.000 description 1
- 230000008880 microtubule cytoskeleton organization Effects 0.000 description 1
- 230000035773 mitosis phase Effects 0.000 description 1
- 150000004682 monohydrates Chemical group 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- 238000011519 second-line treatment Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
- C07D305/14—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Epoxy Compounds (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA2909500A CA2909500C (en) | 2012-07-25 | 2013-07-18 | Crystal form of cabazitaxel and preparation method thereof |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210259595.3 | 2012-07-25 | ||
| CN201210259595.3A CN102746258B (zh) | 2012-07-25 | 2012-07-25 | 卡巴他赛的结晶形式及其制备方法 |
| PCT/CN2013/079575 WO2014015760A1 (zh) | 2012-07-25 | 2013-07-18 | 卡巴他赛的结晶形式及其制备方法 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2909500A Division CA2909500C (en) | 2012-07-25 | 2013-07-18 | Crystal form of cabazitaxel and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2870569A1 true CA2870569A1 (en) | 2014-01-30 |
Family
ID=47026807
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2870569A Abandoned CA2870569A1 (en) | 2012-07-25 | 2013-07-18 | Crystal form of cabazitaxel and preparation method thereof |
| CA2909500A Active CA2909500C (en) | 2012-07-25 | 2013-07-18 | Crystal form of cabazitaxel and preparation method thereof |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2909500A Active CA2909500C (en) | 2012-07-25 | 2013-07-18 | Crystal form of cabazitaxel and preparation method thereof |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US9353076B2 (enExample) |
| EP (2) | EP2835369B1 (enExample) |
| JP (1) | JP6329135B2 (enExample) |
| CN (1) | CN102746258B (enExample) |
| AU (2) | AU2013295924B2 (enExample) |
| CA (2) | CA2870569A1 (enExample) |
| IN (1) | IN2014MN01962A (enExample) |
| WO (1) | WO2014015760A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2688877B1 (en) | 2011-04-12 | 2017-03-08 | Teva Pharmaceuticals International GmbH | Solid state forms of cabazitaxel and processes for preparation thereof |
| CN104220431A (zh) * | 2012-03-08 | 2014-12-17 | 伊瓦克斯国际有限责任公司 | 卡巴他赛的固态形式及其制备方法 |
| CN102746258B (zh) * | 2012-07-25 | 2015-02-04 | 重庆泰濠制药有限公司 | 卡巴他赛的结晶形式及其制备方法 |
| CN103804323A (zh) * | 2012-11-14 | 2014-05-21 | 上海希迈医药科技有限公司 | 一种卡巴他赛溶剂化物及其制备方法和应用 |
| CN103819428B (zh) * | 2012-11-19 | 2016-01-13 | 齐鲁制药有限公司 | 7β,10β-二甲氧基多西紫杉醇的溶剂化物的晶型及其制备方法 |
| CN103058960B (zh) * | 2012-12-12 | 2014-12-10 | 江苏奥赛康药业股份有限公司 | 卡巴他赛多晶型形式及其制备方法 |
| KR101429543B1 (ko) | 2012-12-13 | 2014-08-14 | 주식회사 삼양바이오팜 | 카바지탁셀의 신규 결정형 및 그 제조방법 |
| CN103044364B (zh) * | 2013-01-07 | 2016-01-20 | 重庆泰濠制药有限公司 | 一种卡巴他赛无定形晶及其制备方法 |
| WO2014128728A2 (en) * | 2013-02-25 | 2014-08-28 | Laurus Labs Private Limited | Solid forms of cabazitaxel and processes for preparation thereof |
| CN103450119B (zh) * | 2013-09-24 | 2015-06-17 | 天津炜捷制药有限公司 | 一种卡巴他赛晶型w及其制备方法 |
| EP2865674A1 (en) * | 2013-10-23 | 2015-04-29 | INDENA S.p.A. | Crystalline solvate forms of Cabazitaxel |
| CN105461664A (zh) * | 2014-08-21 | 2016-04-06 | 中国医学科学院药物研究所 | 卡巴他赛晶n5型物质及制备方法和其组合物与用途 |
| CN105461665A (zh) * | 2014-08-21 | 2016-04-06 | 中国医学科学院药物研究所 | 卡巴他赛晶n6型物质及制备方法和其组合物与用途 |
| CA3010514A1 (en) | 2016-01-15 | 2017-07-20 | Zhuhai Beihai Biotech Co., Ltd. | Compositions and formulations including cabazitaxel and human serum albumin |
| EP3509569A1 (en) * | 2016-09-07 | 2019-07-17 | Cadila Healthcare Limited | Sterile injectable compositions comprising drug micelles |
| CN112055588B (zh) | 2018-04-20 | 2023-09-08 | 珠海贝海生物技术有限公司 | 卡巴他赛的制剂和组合物 |
| CN113429369B (zh) * | 2021-07-23 | 2022-12-02 | 无锡紫杉药业有限公司 | 一种高效的卡巴他赛纯化方法 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SK9742002A3 (en) | 2000-01-07 | 2003-02-04 | Transform Pharmaceuticals Inc | High-throughput formation, identification, and analysis of diverse solid-forms |
| FR2859996B1 (fr) * | 2003-09-19 | 2006-02-03 | Aventis Pharma Sa | Solvat acetonique du dimethoxy docetaxel et son procede de preparation |
| FR2926551A1 (fr) * | 2008-01-17 | 2009-07-24 | Aventis Pharma Sa | Formes cristallines du dimethoxy docetaxel et leurs procedes de preparation |
| CN101525321B (zh) * | 2008-03-06 | 2012-03-07 | 上海希迪制药有限公司 | 多烯紫杉醇倍半水结晶体及其制备方法 |
| PL388144A1 (pl) | 2009-05-29 | 2010-12-06 | Przedsiębiorstwo Produkcyjno-Wdrożeniowe Ifotam Spółka Z Ograniczoną Odpowiedzialnością | Solwaty (2R,3S)-3-tert-butoksykarbonylamino-2-hydroksy-3-fenylopropionianu 4-acetoksy-2α-benzoiloksy -5β,20-epoksy-1,7β,10β-trihydroksy-9-okso-taks-11-en-13α-ylu, sposób ich otrzymywania i zastosowanie |
| CN102060815B (zh) * | 2010-12-24 | 2012-09-26 | 重庆泰濠制药有限公司 | 一种紫杉烷类化合物的制备方法 |
| EP2688877B1 (en) * | 2011-04-12 | 2017-03-08 | Teva Pharmaceuticals International GmbH | Solid state forms of cabazitaxel and processes for preparation thereof |
| TWI526437B (zh) | 2011-09-09 | 2016-03-21 | 台灣神隆股份有限公司 | 卡巴他賽之結晶型 |
| CN102336726B (zh) * | 2011-09-30 | 2014-11-26 | 重庆泰濠制药有限公司 | 一种卡巴他赛的制备方法 |
| US9772339B2 (en) * | 2011-09-30 | 2017-09-26 | Life Technologies Corporation | Methods and systems for image analysis identification |
| CN102503913B (zh) * | 2011-10-20 | 2014-03-26 | 江苏红豆杉生物科技股份有限公司 | 直接用于x射线单晶衍射分析的二甲氧基紫杉烷类化合物单晶晶体的制备方法 |
| DE112012004569T5 (de) * | 2011-11-01 | 2014-08-14 | Fresenius Kabi Oncology Ltd. | Amorphe Form von Cabazitaxel und Verfahren zum Herstellen davon |
| PL2785701T3 (pl) * | 2011-11-28 | 2019-08-30 | Fresenius Kabi Oncology Limited | Krystaliczna postać kabazytakselu i sposób jej otrzymywania |
| JP6025861B2 (ja) * | 2011-12-13 | 2016-11-16 | アベンティス・ファーマ・ソシエテ・アノニム | カバジタキセルの結晶形およびこれを調製するための方法 |
| CN104220431A (zh) * | 2012-03-08 | 2014-12-17 | 伊瓦克斯国际有限责任公司 | 卡巴他赛的固态形式及其制备方法 |
| CN102746258B (zh) | 2012-07-25 | 2015-02-04 | 重庆泰濠制药有限公司 | 卡巴他赛的结晶形式及其制备方法 |
| CN104583189A (zh) * | 2012-07-31 | 2015-04-29 | 永信药品工业股份有限公司 | 非晶型的卡巴利他索 |
| CN102898406B (zh) * | 2012-11-02 | 2014-12-03 | 上海金和生物技术有限公司 | 一种卡巴他赛晶体及其制备方法 |
| CN103058960B (zh) * | 2012-12-12 | 2014-12-10 | 江苏奥赛康药业股份有限公司 | 卡巴他赛多晶型形式及其制备方法 |
-
2012
- 2012-07-25 CN CN201210259595.3A patent/CN102746258B/zh active Active
-
2013
- 2013-07-18 WO PCT/CN2013/079575 patent/WO2014015760A1/zh not_active Ceased
- 2013-07-18 JP JP2015514346A patent/JP6329135B2/ja active Active
- 2013-07-18 EP EP13822828.3A patent/EP2835369B1/en active Active
- 2013-07-18 US US14/399,513 patent/US9353076B2/en active Active
- 2013-07-18 CA CA2870569A patent/CA2870569A1/en not_active Abandoned
- 2013-07-18 IN IN1962MUN2014 patent/IN2014MN01962A/en unknown
- 2013-07-18 EP EP16162975.3A patent/EP3067348A1/en not_active Withdrawn
- 2013-07-18 AU AU2013295924A patent/AU2013295924B2/en active Active
- 2013-07-18 CA CA2909500A patent/CA2909500C/en active Active
-
2016
- 2016-01-21 AU AU2016200343A patent/AU2016200343B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN102746258B (zh) | 2015-02-04 |
| CA2909500A1 (en) | 2014-01-30 |
| US20150141674A1 (en) | 2015-05-21 |
| CN102746258A (zh) | 2012-10-24 |
| WO2014015760A1 (zh) | 2014-01-30 |
| EP3067348A1 (en) | 2016-09-14 |
| AU2013295924B2 (en) | 2016-02-18 |
| EP2835369A4 (en) | 2015-12-02 |
| AU2013295924A1 (en) | 2014-10-23 |
| EP2835369B1 (en) | 2019-04-03 |
| JP2015518012A (ja) | 2015-06-25 |
| AU2016200343B2 (en) | 2017-03-30 |
| IN2014MN01962A (enExample) | 2015-07-10 |
| US9353076B2 (en) | 2016-05-31 |
| JP6329135B2 (ja) | 2018-05-23 |
| CA2909500C (en) | 2018-01-09 |
| EP2835369A1 (en) | 2015-02-11 |
| AU2016200343A1 (en) | 2016-02-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2909500C (en) | Crystal form of cabazitaxel and preparation method thereof | |
| TWI526437B (zh) | 卡巴他賽之結晶型 | |
| JP6190079B2 (ja) | ３，５−二置換ベンゼンアルキニル化合物の結晶 | |
| EP3248983A1 (en) | Crystal form a of obeticholic acid and preparation method therefor | |
| AU2016260279A1 (en) | Crystals of azabicyclic compound | |
| US11639341B2 (en) | Crystal form of tipifarnib and method of treatment thereof | |
| CN114727994B (zh) | 优替德隆半水合物单晶及其制备方法与应用 | |
| KR101596554B1 (ko) | 펩타이드계 물질의 결정체 및 그의 제조방법과 용도 | |
| WO2012160568A1 (en) | Process for preparing docetaxel trihydrate polymorph | |
| CN108440626B (zh) | 阿糖胞苷5′-o-l-缬氨酸酯盐酸盐的晶型及其制备方法 | |
| RU2712169C2 (ru) | Новые полиморфные формы икотиниба фосфата и их применения | |
| EP3088402A1 (en) | CRYSTALS (2) OF PYRAZINO[2,1-c][1,2,4]TRIAZINE COMPOUND | |
| WO2017042837A2 (en) | Stable crystalline form of regadenoson | |
| JP2018510173A (ja) | トピロキソスタットの新規結晶形及びその製造方法 | |
| CN105636964B (zh) | L‑丙氨酸‑(14‑冬凌草甲素)酯三氟乙酸盐的i型结晶及制备方法 | |
| WO2018051239A1 (en) | Process for the preparation of pure and stable crystalline raltegravir potassium form 3 | |
| CN107629048B (zh) | 一种酪氨酸激酶抑制剂的苹果酸盐的结晶形式及其制备方法 | |
| CA3034535A1 (en) | Novel salt of (r)-(1-methylpyrrolidine-3-yl)methyl(3'-chloro-4'-fluoro-[1,1'-biphenyl]-2-yl)carbamate and a crystal form thereof | |
| CN106279192B (zh) | 一种喹唑啉衍生物盐酸盐的结晶多晶型物 | |
| CN104892574A (zh) | 达比加群酯甲磺酸盐的晶型及其制备方法和用途 | |
| WO2011066735A1 (en) | An Amorolfine HCl Crystal and the Preparation thereof | |
| WO2013164857A1 (en) | Desvenlafaxine succinate solid dispersion |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20141016 |
|
| FZDE | Dead |
Effective date: 20181213 |